Propel Bio Management LLC trimmed its stake in shares of Athira Pharma, Inc. (NASDAQ:ATHA – Free Report) by 90.0% in the third quarter, Holdings Channel.com reports. The firm owned 149,279 shares of the company’s stock after selling 1,343,513 shares during the quarter. Athira Pharma comprises approximately 0.6% of Propel Bio Management LLC’s investment portfolio, making the stock its 16th biggest position. Propel Bio Management LLC’s holdings in Athira Pharma were worth $618,000 as of its most recent SEC filing.
Separately, BML Capital Management LLC grew its stake in shares of Athira Pharma by 0.9% during the second quarter. BML Capital Management LLC now owns 3,230,667 shares of the company’s stock worth $976,000 after buying an additional 30,000 shares during the last quarter. 57.12% of the stock is owned by hedge funds and other institutional investors.
Athira Pharma Stock Performance
Shares of NASDAQ:ATHA opened at $5.57 on Thursday. Athira Pharma, Inc. has a 52-week low of $2.20 and a 52-week high of $8.36. The company has a market capitalization of $21.97 million, a PE ratio of -0.58 and a beta of 2.79. The company has a fifty day moving average of $5.85 and a 200-day moving average of $4.80.
Athira Pharma Company Profile
Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).
The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.
Recommended Stories
- Five stocks we like better than Athira Pharma
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Want to see what other hedge funds are holding ATHA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Athira Pharma, Inc. (NASDAQ:ATHA – Free Report).
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
